BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11815964)

  • 1. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
    Ryan DP; Kulke MH; Fuchs CS; Grossbard ML; Grossman SR; Morgan JA; Earle CC; Shivdasani R; Kim H; Mayer RJ; Clark JW
    Cancer; 2002 Jan; 94(1):97-103. PubMed ID: 11815964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
    Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
    Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
    Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
    Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
    Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
    Mekhail T; Hutson TE; Elson P; Budd GT; Srkalovic G; Olencki T; Peereboom D; Pelley R; Bukowski RM
    Cancer; 2003 Jan; 97(1):170-8. PubMed ID: 12491518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
    Dreicer R; Manola J; Schneider DJ; Schwerkoske JF; George CS; Roth BJ; Wilding G;
    Cancer; 2003 Jun; 97(11):2743-7. PubMed ID: 12767086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
    Laufman LR; Spiridonidis CH; Pritchard J; Roach R; Zangmeister J; Larrimer N; Moore T; Segal M; Jones J; Patel T; Gutterman L; Carman L; Colborn D; Kuebler JP
    Ann Oncol; 2001 Sep; 12(9):1259-64. PubMed ID: 11697837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
    Cascinu S; Gasparini G; Catalano V; Silva RR; Pancera G; Morabito A; Giordani P; Gattuso D; Catalano G
    Ann Oncol; 1999 Nov; 10(11):1377-9. PubMed ID: 10631469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
    Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
    Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
    Chen YM; Perng RP; Lin WC; Wu HW; Tsai CM; Whang-Peng J
    Am J Clin Oncol; 2002 Oct; 25(5):509-12. PubMed ID: 12393994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study.
    Schneider BP; Ganjoo KN; Seitz DE; Picus J; Fata F; Stoner C; Calley C; Loehrer PJ
    Oncology; 2003; 65(3):218-23. PubMed ID: 14657595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.
    Stathopoulos GP; Mavroudis D; Tsavaris N; Kouroussis C; Aravantinos G; Agelaki S; Kakolyris S; Rigatos SK; Karabekios S; Georgoulias V
    Ann Oncol; 2001 Jan; 12(1):101-3. PubMed ID: 11249034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
    Ryan DP; Lynch TJ; Grossbard ML; Seiden MV; Fuchs CS; Grenon N; Baccala P; Berg D; Finkelstein D; Mayer RJ; Clark JW
    Cancer; 2000 Jan; 88(1):180-5. PubMed ID: 10618622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
    J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
    Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
    Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
    Lutz MP; Van Cutsem E; Wagener T; Van Laethem JL; Vanhoefer U; Wils JA; Gamelin E; Koehne CH; Arnaud JP; Mitry E; Husseini F; Reichardt P; El-Serafi M; Etienne PL; Lingenfelser T; Praet M; Genicot B; Debois M; Nordlinger B; Ducreux MP;
    J Clin Oncol; 2005 Dec; 23(36):9250-6. PubMed ID: 16361622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
    Jacobs AD; Otero H; Picozzi VJ; Aboulafia DM
    Cancer Invest; 2004; 22(4):505-14. PubMed ID: 15565807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.